

## LncRNA LINC01116 Contributes to Cisplatin Resistance in Lung Adenocarcinoma [Retraction]

Wang J, Gao J, Chen Q, et al. *Onco Targets Ther.* 2020;13:9333–9347.

At the authors request, we the Editor and Publisher of *OncoTargets and Therapy* are retracting the published article. Concerns were raised to the authors attention regarding the duplication of images in Figures 2 and 5. Specifically,

- Images from Figure 2E, Invasion, si-LINC1116 1# and si-LINC01116 2#, were duplicated.
- Images from Figure 5E, Migration, Empty vector and Invasion, Empty vector and pcDNA-LINC0116 were duplicated.

The authors explained that errors had been made during the preparation of the figures, but no original data was provided to the journal. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article. The editor agreed with this decision.

We have been informed in our decision-making by our editorial policies and the COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.

### Publish your work in this journal

OncoTargets and Therapy is an international, peer-reviewed, open access journal focusing on the pathological basis of all cancers, potential targets for therapy and treatment protocols employed to improve the management of cancer patients. The journal also focuses on the impact of management programs and new therapeutic agents and protocols on patient perspectives such as quality of life, adherence and satisfaction. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/oncotargets-and-therapy-journal>

<https://doi.org/10.2147/OTT.S430432>